SHMT2-RES Citations (1)

Originally described in: SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance.
Kim D, Fiske BP, Birsoy K, Freinkman E, Kami K, Possemato RL, Chudnovsky Y, Pacold ME, Chen WW, Cantor JR, Shelton LM, Gui DY, Kwon M, Ramkissoon SH, Ligon KL, Kang SW, Snuderl M, Vander Heiden MG, Sabatini DM Nature. 2015 Apr 16;520(7547):363-7. doi: 10.1038/nature14363. Epub 2015 Apr 8. PubMed Journal

---

Articles Citing SHMT2-RES

Articles
Metformin Is a Pyridoxal-5'-phosphate (PLP)-Competitive Inhibitor of SHMT2. Tramonti A, Cuyas E, Encinar JA, Pietzke M, Paone A, Verdura S, Arbusa A, Martin-Castillo B, Giardina G, Joven J, Vazquez A, Contestabile R, Cutruzzola F, Menendez JA. Cancers (Basel). 2021 Aug 9;13(16). pii: cancers13164009. doi: 10.3390/cancers13164009. PubMed

If you have published an article using this material, please email us at to have your article added to this page.